Hoersholm, Denmark; 21 February, 2015 - Medical Prognosis Institute A/S (MPI.CO) has in collaboration with the Danish University Hospital Rigshospitalet, Department of Hematology published data showing that MPI's biomarker DRP(TM) may help identifying which patients suffering from Diffuse Large B-Cell Lymphoma (DLBCL) are likely to respond to standard treatment with combinations (R- CHO(E)P). These results have been published in PLOS ONE, an international, peer-reviewed, open-access, online publication in which the results appear under the title 'Development and blind clinical validation of microRNA based predictor of response to treatment with R-CHO(E)P in DLBCL'. In a cohort of 116 de novo patients suffering from DLBCL, MPI correctly predicted who were likely to respond to the standard first line treatment with (R-CHO(E)P) - and who were not likely to respond. Data from this investigation suggest that survival can be improved if MPI's biomarker DRP(TM) is used to select the optimal treatment in second and third line therapy. The results require further validation in a larger cohort of relapsed DLBCL patients for the DRP's potential clinical utility in second and third line treatment. MPI has developed predictive miRNA profiles for DLBCL patients that can identify patients that will respond poorly to treatment with CHOP. The prediction is carried out by analyzing of small pieces of RNA, microRNA from the tumor. Research has shown that microRNA is active opening and closing the genes in cancer and therefore also sensitivity to cancer drugs. As more than 80% of patients respond to first line treatment the high medical need and potential clinical utility lies in second and third line treatment, however, where the probability of response is smaller, and the number of available treatment options is large. Our results show that there is a potential that the predictor can assist in the selection of the optimal treatment. Read the full publication: http://www.ncbi.nlm.nih.gov/pubmed/25692889 "Our aim in MPI is that our DRP can support doctors selecting the most optimal treatment for the benefit of the patient. The results achieved in collaboration with leading Danish cancer doctor's shows that we with high probability can help patients with relapsed lymph node cancer," said Professor, Peter Buhl Jensen, M.D., CEO of MPI. "We are pleased to publish yet another clinical validation of our DRP® technology," noted Dr. Steen Knudsen, Ph.D., CSO and Co-Founder of MPI. About MPI's genetic response profile called Drug Response Predictor (DRP(TM)) MPI's lead product, the DRP(TM) diagnostic platform, is a tool to develop tumor- derived gene signatures that may predict which cancer patients are highly likely responders to a given anticancer product. The DRP(TM) has been tested in 26 trials, where 22 trials showed that drug-specific DRP(TM) Biomarkers could predict which patients had a positive effect of the treatment. The DRP(TM) platform has also been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP(TM) method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given anticancer drug. Further to and in addition to this, individual patients' gene patterns can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of those patients who have a high likelihood of response to the drug. The DRP(TM) platform can be used in all cancer types and has been patented for more than 60 anticancer drugs in the US. About MPI Medical Prognosis Institute, Inc. advances personalized medicine by partnering with cancer drug developers to apply its DRP(TM) diagnostic platform to streamline and de-risk clinical trials and drug development via biomarker optimization, patient stratification, and development of companion diagnostics. For further information, please contact CEO Peter Buhl Jensen, Professor, MD, Ph.D. E-mail: pbj@medical-prognosis.com Cell Phone: (+45) 21 60 89 22 Certified Advisor: Carsten Yde Hemme, PricewaterhouseCoopers, Strandvejen 44, 2900 Hellerup, Denmark [HUG#1896352]
MPI's DPR technology predicts which lymphoma patients
Top 10 Most Recent News Articles
Berry Street Integrates AI with What Matters: Human Touch
Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...
Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data
Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...
Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact
A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...
Continue Reading
Princess Cruises Launches New Era at Celebration Key
Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...
Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit
High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...
Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries
JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...
Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss
Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...
Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle
IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...
Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake
Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...
Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control
Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...
Continue ReadingTop 5 Most Recently Viewed Articles
HUB Cyber Security's Roadmap for Revolutionary Financial Solutions
HUB Cyber Security Unveils Revolutionary Financial Solutions HUB Cyber Security Ltd. (Nasdaq: HUBC) has shared an ambitious roadmap to launch the HUB Token (HUBT), positioning itself as a pioneer in the rapidly evolving digital finance landscape. This strategic initiative aims to power the innovative Trvsthub™ platform, which promises to enhance the security and...
Continue Reading
MSU Energy Completes Successful Exchange Offer for Senior Notes
MSU Energy Completes Successful Exchange of Senior Notes MSU Energy S.A. has announced the results of its recent exchange offer, which culminated successfully within an established timeframe. This initiative involved an exchange for up to $218,973,000 in aggregate principal amount of its existing 6.875% Senior Notes due 2025. The transition to new financial instruments...
Continue Reading
Major Defense Contracts Awarded to Lockheed and Boeing
The Pentagon's New Contracts The recent contracts awarded by the Pentagon to Lockheed Martin Corporation (NYSE: LMT) and Boeing Company (NYSE: BA) exemplify the ongoing investment in national defense. These new agreements underscore a robust financial commitment to enhancing military capabilities. Lockheed Martin's Taiwan FMS Award Lockheed Martin has secured a pivotal...
Continue Reading
Maryland Army National Guard's General Birckhead to Address Graduates
General Janeen L. Birckhead to Inspire Graduates at HCC Columbia, MD — A significant moment is approaching for over 1,100 graduates of Howard Community College (HCC) as they prepare to celebrate their accomplishments at the upcoming commencement exercises. The keynote speaker for this year's ceremony is none other than Major General Janeen L. Birckhead, Adjutant General...
Continue Reading
SUNation Energy Announces Participation in Annual Roth Conference
SUNation Energy to Engage in Investment Discussions SUNation Energy, Inc. (Nasdaq: SUNE), a prominent provider of solar energy and power solutions, has made it's presence known as it prepares to take part in a significant investor conference. The upcoming event, known as the Annual Roth Conference, serves as a pivotal platform where growth companies showcase their...
Continue Reading